Strategic partnerships Shasqi’s CAPAC platform and click-activated protodrugs targeting cancer at the tumor site presents a compelling collaboration opportunity with pharmaceutical companies seeking to improve therapeutic index and reduce systemic toxicity. Propose co-development or licensing discussions with biotech and large pharma players focused on oncology expansion and precision therapeutics.

Clinical and financial momentum With ongoing clinical-stage programs, recent leadership hires in finance and business development, and a total funding of sixty-five million dollars, Shasqi demonstrates growth velocity and credibility that can de-risk partnerships and attract co-funding for expansion into additional indications or combination therapies.

Expansion potential Recent collaborations and expansions, including Johnson & Johnson Enterprise Innovation engagement, signal appetite for broader research partnerships. Target large-cap and mid-market biotech firms exploring antibody-mediated tumor targeting and payload diversification to extend CAPAC library applications.

Technology differentiator Shasqi’s proprietary CAPAC platform offers tumor-localized activation with potentially higher therapeutic index. This unique value proposition is attractive for contract research organizations and clinical development partnerships aiming to enhance oncology drug efficacy while mitigating toxicity.

Market readiness Operating with a lean team (11-50 employees) yet validated by funding rounds and press, Shasqi is positioned to explore milestone-driven partnerships, co-development deals, and sponsored research agreements to accelerate pipeline progress while balancing risk and resource allocation.